LIQUIDIA CORPORATION Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount
LIQUIDIA CORPORATION (LQDA) reported Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount of $1.93 million for the 12-month period ending 2024-12-31, per its 8-K filed 2025-05-08.
Financial Statements › Notes › Income Taxes
us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount · last filed 2025-05-08
- LIQUIDIA CORPORATION effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2022 was $310.00K, a 8.39% increase from fiscal 2021.
- LIQUIDIA CORPORATION effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2021 was $286.00K, a 15.78% increase from fiscal 2020.
- LIQUIDIA CORPORATION effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2020 was $247.01K, a 4.38% decline from fiscal 2019.
- LIQUIDIA CORPORATION effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2019 was $258.34K.
| Period end | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount 12 month | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount 12 month as first filed |
|---|---|---|
| 2024-12-31 | $1.93M 8-K · filed 2025-05-08 | |
| 2023-12-31 | $2.02M 8-K · filed 2025-05-08 | |
| 2022-12-31 | $310.00K 10-K · filed 2024-03-13 | |
| 2021-12-31 | $286.00K 10-K · filed 2023-03-20 | $286.23K 10-K · filed 2022-03-17 |
| 2020-12-31 | $247.01K 10-K · filed 2022-03-17 | |
| 2019-12-31 | $258.34K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |